

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

GENOME THERAPEUTICS CORP

Form 8-K

January 02, 2003

=====

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to
Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 2, 2003

GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)

Massachusetts	0-10824	04-2297484
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

100 Beaver Street
Waltham, Massachusetts 02453

(Address, of principal executive offices, including zip code)

(781) 398-2300

(Registrant's Telephone number including area code)

Page 1 of 4 pages.

Item 5. OTHER EVENTS

On January 2, 2003, Genome Therapeutics Corp. issued a press release announcing that it has established an alliance with Amgen Inc. for the identification and development of novel therapeutic agents for bone diseases, including osteoporosis. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

-2-

SIGNATURES

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ Steven Rauscher

Name: Steven Rauscher

Title: Chief Executive Officer

Date: January 2, 2003

EXHIBIT INDEX

99.1 Press Release dated January 2, 2003